Iterum Therapeutics Prepares for ORLYNVAH™ Launch

Iterum Therapeutics ( (ITRM) ) has released its Q1 earnings. Here is a breakdown of the information Iterum Therapeutics presented to its investors.

Iterum Therapeutics, a biopharmaceutical company, is dedicated to developing innovative oral and IV antibiotics to combat infections caused by multi-drug resistant pathogens in both community and hospital settings.

In its latest earnings report, Iterum Therapeutics announced its financial results for the first quarter of 2025, highlighting preparations for the potential launch of ORLYNVAH™, an oral antibiotic for uncomplicated urinary tract infections, by the fourth quarter of 2025. The company also extended its cash runway into 2026.

Key financial metrics include a net loss of $4.9 million for the first quarter of 2025, an improvement from the $7.1 million loss in the same period of 2024. The company raised approximately $6 million through direct offerings and at-the-market programs, ensuring sufficient funds to support operations into 2026. Additionally, Iterum repaid its 6.500% Exchangeable Senior Subordinated Notes due in 2025.

Iterum’s strategic focus remains on the commercialization of ORLYNVAH™ in the U.S. market, addressing the urgent need for new treatment options for urinary tract infections. The company is exploring strategic transactions to maximize the value of its sulopenem rights.

Looking ahead, Iterum Therapeutics is poised for a potential market launch of ORLYNVAH™ by late 2025, with management expressing confidence in their financial positioning and strategic initiatives to bring this much-needed antibiotic to patients.